MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)

Phase 3

Terminated

• Conditions: Diabetes Mellitus, Type 2

• Registration Number: NCT00543816
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

This study will look to see if MK0767 works better than placebo in controlling blood sugar in patients with Type 2 Diabetes who are taking insulin but do not have adequate control of their blood sugar.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Detailed Description

Not available

Study Timeline

• Study Start: 2003-08
• Primary Completion: 2003-11
• Study Completion: 2003-11
• Study First Submitted: 2007-10-05
• Study First Submitted QC: 2007-10-12
• Study First Posted: 2007-10-15
• Status Verified: 2015-06
• Last Update Submitted: 2015-06-22
• Last Update Posted: 2015-06-23

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Type 2 Diabetes with inadequate glycemic control
• Patient is on stable insulin therapy alone or with one oral antidiabetic agent
• Male or non-pregnant female 21 years or older
• Total daily dose of insulin must be less than or equal to 30 but not greater than or equal to 200 units/day

Read More

Exclusion Criteria

• Have a history of type 1 diabetes mellitus
• History of ketoacidosis who are being treated with insulin
• Are taking 2 or more antidiabetic agents in combination with insulin

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL